p53 Is Abnormally Elevated and Active in the CNS of Patients with Amyotrophic Lateral Sclerosis
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Motor neuron degeneration in amyotrophic lateral sclerosis (ALS) is a form of apoptosis, but the mechanisms for this neuronal cell death are not known. We evaluated whether motor neuron degeneration in ALS is associated with changes in the levels and function of the apoptosis regulating protein p53. The protein levels and localizations of p53 are abnormal in ALS. By immunoblotting, p53 is elevated in the nuclear compartment of selectively vulnerable CNS regions in individuals with ALS compared to age-matched controls. The levels of a carboxyl-terminal degradation fragment of p53 were decreased in cases of ALS. DNA binding assay demonstrated that the increased p53 in individuals with ALS had competent DNA binding activity. Immunocytochemistry revealed that in normal human CNS p53 is expressed in subsets of nonneuronal cells, but it is found only rarely in neurons; in contrast, in individuals with ALS, p53 is frequently found in motor neurons of spinal cord and motor cortex and is upregulated in astroglia. It is concluded that p53 may participate in the mechanisms for motor neuron apoptosis in ALS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
Toshiyuki, M., & Reed, J. C. (1995) · Cell · doi:10.1016/0092-8674(95)90412-3 · Cited by 4,063
A model for p53-induced apoptosis
Polyak, K., Xia, Y., Zweier, J. L., Kinzler, K. W., & Vogelstein, B. (1997) · Nature · doi:10.1038/38525 · Cited by 2,500
NeuN, a neuronal specific nuclear protein in vertebratesxs
Mullen, R. J., Buck, C. R., & Smith, A. M. (1992) · Development · doi:10.1242/dev.116.1.201 · Cited by 2,351
Cited by
Targeting programmed cell death in neurodegenerative diseases
Vila, M., & Przedborski, S. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1100 · Cited by 546
Culmsee, C., & Mattson, M. P. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.149 · Cited by 389
Epigenetic Regulation of Motor Neuron Cell Death through DNA Methylation
Chestnut, B. A., Chang, Q., Price, A., Lesuisse, C., Wong, M., & Martin, L. J. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.1639-11.2011 · Cited by 362
Self-citationLong‐term culture of mouse cortical neurons as a model for neuronal development, aging, and death
Lesuisse, C., & Martin, L. J. (2002) · Journal of Neurobiology · doi:10.1002/neu.10037 · Cited by 262
Self-citationOptineurin suppression causes neuronal cell death via NF‐κB pathway
Akizuki, M., Yamashita, H., Uemura, K., Maruyama, H., Kawakami, H., Ito, H., & Takahashi, R. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12326 · Cited by 96
De Santis, R., Santini, L., Colantoni, A., Peruzzi, G., de Turris, V., Alfano, V., Bozzoni, I., & Rosa, A. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.09.004 · Cited by 91
“…here that p53 and other pro-apoptotic miR-375 predicted targets are upregulated in FUS mutant MNs. Notably, spinal MNs of ALS patients have been shown to display higher levels of p53 protein, which could be involved in apoptosis-mediated neuronal death (Martin, 2000; Ranganathan and Bowser, 2010).”
Trias, E., Beilby, P. R., Kovacs, M., Ibarburu, S., Varela, V., Barreto-Núñez, R., Bradford, S. C., Beckman, J. S., & Barbeito, L. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00042 · Cited by 85
p53: from understanding its structure to advances in therapeutic targeting
Wang, W., Liu, X., Liu, H., Abolhassani, H., Yan, H., Zhang, H., & Wang, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02549-5 · Cited by 30
Metadata
- Authors
- Martin, L. J.
- Venue
- Neurobiology of Disease
- Publisher
- Elsevier BV
- Published
- 2000-12
- Volume
- 7
- Issue
- 6
- Pages
- 613-622
- ISSN
- 0969-9961 (ISSN-L)
- OpenAlex
- W2086943561
- Cited by
- 135
- References
- 3
- FWCI
- 5.55
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.